Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-Current Assets (2016 - 2025)

Celldex Therapeutics has reported Non-Current Assets over the past 16 years, most recently at $48.3 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $48.3 million for Q4 2025, up 6.95% from a year ago — trailing twelve months through Dec 2025 was $182.1 million (up 16.27% YoY), and the annual figure for FY2025 was $48.3 million, up 6.95%.
  • Non-Current Assets for Q4 2025 was $48.3 million at Celldex Therapeutics, up from $44.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CLDX hit a ceiling of $48.3 million in Q4 2025 and a floor of $33.3 million in Q1 2022.
  • Median Non-Current Assets over the past 5 years was $35.0 million (2022), compared with a mean of $37.8 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 36.33% in 2021 and later skyrocketed 36.37% in 2025.
  • Celldex Therapeutics' Non-Current Assets stood at $33.8 million in 2021, then increased by 3.63% to $35.0 million in 2022, then decreased by 3.16% to $33.9 million in 2023, then surged by 33.14% to $45.2 million in 2024, then grew by 6.95% to $48.3 million in 2025.
  • The last three reported values for Non-Current Assets were $48.3 million (Q4 2025), $44.1 million (Q3 2025), and $44.0 million (Q2 2025) per Business Quant data.